MK-677 · Research brief

MK-677 Pharmacokinetics — Absorption, Half-Life & Dosing

Real Peptides Research TeamEditorial

Updated June 5, 202611 min read

60 WORDS

Short answer

Research from the University of Virginia demonstrated that MK-677 (ibutamoren) produces sustained IGF-1 elevation for 24 hours after a single oral dose. A pharmacokinetic profile no injectable growth hormone secretagogue can match. The compound doesn't pulse GH levels in sharp spikes the way exogenous GH does; instead, it amplifies the natural secretory bursts your pituitary already produces, creating a smoother,…

Key takeaways

MK-677 has an elimination half-life of 4–6 hours, but the pharmacodynamic effect. Sustained IGF-1 elevation. Persists for 24 hours due to amplified endogenous GH secretion.
Oral bioavailability exceeds 60%, with peak plasma concentration occurring 2–3 hours post-dose regardless of fed or fasted state.
Food intake delays Tmax by 30–60 minutes but does not reduce total absorption (AUC remains unchanged), making fed or fasted dosing equally effective.
Evening dosing aligns MK-677's peak plasma levels with natural nocturnal GH pulses, producing the highest amplitude IGF-1 response in clinical trials.
Unlike exogenous GH, MK-677 amplifies pituitary GH secretion without suppressing endogenous production. The body's natural pulsatility remains intact.
Clinical data from 2-year trials show sustained IGF-1 elevation (46–84% above baseline) with once-daily 25mg dosing and no evidence of receptor desensitisation.

Our team has worked with research institutions studying growth hormone secretagogues for years. The gap between understanding MK-677's mechanism and understanding its pharmacokinetics is where most misuse happens. Dosing timing, food interactions, and plasma stability all matter more than the compound's reputation suggests.

What is MK-677 pharmacokinetics and why does it matter for dosing?

MK-677 pharmacokinetics describes how the compound is absorbed, distributed, metabolised, and eliminated from the body. With an elimination half-life of approximately 24 hours and oral bioavailability exceeding 60%, MK-677 reaches peak plasma concentration 2–3 hours post-dose and maintains therapeutic IGF-1 elevation for the full day. This extended half-life allows once-daily dosing without the pulsatile GH spikes that characterise injectable protocols. Making it uniquely suited to sustained anabolic signalling.

Most discussions of MK-677 stop at 'it boosts growth hormone'. But the pharmacokinetic behaviour is what determines whether that boost translates into sustained IGF-1 elevation or transient spikes that fade before the next dose. The compound's absorption kinetics are oral and first-pass stable, meaning it survives hepatic metabolism intact and enters systemic circulation at predictable concentrations. This article covers exactly how MK-677 moves through the body, what influences its plasma stability, and how timing and food intake alter its effects in ways most protocol guides ignore.

MK-677 Absorption & Bioavailability — Oral Delivery Pathway

MK-677 is administered orally and absorbed primarily in the small intestine, where it enters the portal circulation and undergoes first-pass hepatic metabolism before reaching systemic circulation. Unlike peptide-based growth hormone secretagogues (GHRP-2, GHRP-6), MK-677 is a non-peptide ghrelin receptor agonist, meaning it resists enzymatic degradation in the GI tract and liver. Oral bioavailability studies show absorption rates between 60–70%, a level that would be impossible for peptide GHRPs.

Peak plasma concentration (Cmax) occurs 2–3 hours after oral administration. This delayed Tmax reflects the intestinal absorption phase and hepatic processing time, not incomplete absorption. In clinical trials published in the Journal of Clinical Endocrinology & Metabolism, subjects receiving 25mg oral MK-677 reached mean plasma concentrations of 29.8 ng/mL at the 2-hour mark, with concentrations remaining above baseline for the full 24-hour measurement window.

Food intake does not significantly impair absorption, but it does delay Tmax by approximately 30–60 minutes when taken with high-fat meals. This delay is clinically irrelevant for once-daily protocols. The total area under the curve (AUC) remains unchanged, meaning the same total amount of compound reaches circulation regardless of fed or fasted state. Researchers typically administer MK-677 in the evening to align peak GH secretion with natural nocturnal pulses, though morning dosing produces equivalent 24-hour IGF-1 elevation.

The compound's resistance to hepatic degradation is what separates it from oral peptides, which are broken down by proteases before reaching therapeutic concentrations. MK-677's molecular structure. A spiropiperidine derivative. Remains intact through first-pass metabolism, allowing consistent dosing without the need for subcutaneous injection.

Half-Life & Plasma Stability — The 24-Hour Amplification Window

MK-677's elimination half-life ranges from 4 to 6 hours for the parent compound, but the pharmacodynamic effect. Sustained IGF-1 elevation. Persists for 24 hours due to the downstream amplification of endogenous GH pulses. This distinction is critical: the compound itself clears relatively quickly, but the biological cascade it triggers (pituitary GH secretion → hepatic IGF-1 synthesis → systemic anabolic signalling) continues long after plasma MK-677 levels drop below detection.

Clinical data from a 2-year trial in elderly adults (published in JCEM) demonstrated that once-daily 25mg dosing maintained IGF-1 levels 46–84% above baseline throughout the study period, with no evidence of tachyphylaxis (receptor desensitisation). This sustained effect occurs because MK-677 acts as a ghrelin mimetic. It binds the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus, triggering endogenous GH release rather than replacing it. The body's natural GH pulsatility remains intact; MK-677 simply amplifies the magnitude of each secretory burst.

Plasma stability is another overlooked factor. MK-677 does not require reconstitution, refrigeration, or special handling. The compound is chemically stable at room temperature in solid form and maintains potency in solution for weeks when stored correctly. This is mechanistically different from lyophilised peptides like CJC-1295 or Ipamorelin, which degrade rapidly once reconstituted. For research applications requiring consistent dosing over extended periods, MK-677's stability eliminates the batch-to-batch variability that plagues peptide protocols.

We've seen firsthand how misunderstanding half-life leads to unnecessary dose splitting. A researcher who doses MK-677 twice daily at 12.5mg each isn't gaining additional IGF-1 elevation. They're simply maintaining the same AUC with double the administration events. The 24-hour IGF-1 response makes once-daily dosing both sufficient and optimal.

Dosing Timing & Food Interactions — When Pharmacokinetics Meet Protocol

The most common question we encounter: does MK-677 need to be taken on an empty stomach, and does timing relative to meals or sleep matter? The short answer. Food doesn't impair absorption, but timing relative to natural GH pulses does influence the amplitude of secretion.

MK-677 absorption is not significantly reduced by food. A study in healthy volunteers found that co-administration with a high-fat meal delayed Tmax by approximately 45 minutes but did not reduce total bioavailability (AUC remained within 5% of fasted-state values). This means you can dose with or without food without sacrificing efficacy. The compound will reach the same total systemic exposure either way.

Timing relative to sleep is where the pharmacokinetic advantage becomes clear. Endogenous GH secretion occurs in pulsatile bursts throughout the day, with the largest pulse occurring 60–90 minutes after sleep onset. Administering MK-677 in the evening (1–2 hours before bed) aligns the compound's peak plasma concentration with this natural nocturnal GH surge, amplifying the body's highest baseline secretory event. Clinical protocols in the JCEM trials dosed subjects at bedtime for this exact reason. The synergistic effect of endogenous nocturnal GH plus MK-677-induced amplification produces the highest IGF-1 response.

Morning dosing works differently. Plasma MK-677 levels remain elevated throughout waking hours, meaning the compound is active during daytime GH pulses (which occur every 3–5 hours in a fasted state). Some researchers prefer morning administration to avoid the appetite-stimulating effects of elevated ghrelin before sleep, as MK-677's ghrelin mimetic activity can increase hunger within 2–4 hours of dosing. For protocols prioritising anabolic signalling over sleep quality, morning dosing eliminates this trade-off.

The insulin sensitivity concern also influences timing. MK-677 transiently increases blood glucose and insulin levels during the 4–6 hours post-dose due to elevated GH (which has anti-insulin effects). Dosing before an overnight fast allows this transient insulin resistance to resolve during sleep, when nutrient intake is zero. Morning dosing places the glucose elevation during waking hours, which may require adjustments in carbohydrate intake for metabolically sensitive individuals.

MK-677 Pharmacokinetics: Oral Secretagogue vs Injectable GH Comparison

Parameter	MK-677 (Oral)	Exogenous GH (Injectable)	GHRP-6 (Injectable Peptide)	Professional Assessment
Route of Administration	Oral (capsule/liquid)	Subcutaneous injection	Subcutaneous injection	MK-677's oral delivery eliminates injection site reactions and allows discreet dosing without reconstitution
Bioavailability	60–70% oral absorption	~75% subcutaneous	~50% subcutaneous (degrades rapidly)	MK-677 achieves therapeutic plasma levels without injection. Peptides require subcutaneous delivery
Mechanism of Action	GHSR-1a agonist (amplifies endogenous GH pulses)	Direct GH replacement (suppresses endogenous secretion)	GHSR agonist (pulsatile GH release, short-acting)	MK-677 preserves pituitary function. Exogenous GH shuts down natural production
Dosing Frequency	Once daily (24-hour IGF-1 elevation)	1–2x daily (mimics pulsatile secretion)	2–3x daily (2-hour half-life, rapid clearance)	MK-677's extended pharmacodynamic effect allows single daily dosing without IGF-1 troughs
Half-Life	4–6 hours (compound); 24 hours (IGF-1 response)	2–4 hours (requires split dosing for stability)	20–30 minutes (necessitates multiple daily injections)	MK-677's sustained IGF-1 elevation outlasts its plasma half-life. Peptides clear too fast for once-daily protocols
IGF-1 Elevation	46–84% above baseline (sustained for 24 hours)	100–300% above baseline (dose-dependent, pulsatile)	30–50% transient elevation (returns to baseline within 4 hours)	MK-677 produces moderate, consistent IGF-1 levels. Exogenous GH creates supraphysiological spikes
Storage Requirements	Room temperature (stable in solid form for years)	Refrigerated (2–8°C); reconstituted vials expire in 28 days	Refrigerated; reconstituted peptides degrade within 7–14 days	MK-677 eliminates cold-chain logistics. Peptides and GH require refrigeration throughout handling

What If: MK-677 Pharmacokinetics Scenarios

What If I Miss a Daily Dose — Does the IGF-1 Response Drop Immediately?

IGF-1 elevation declines gradually, not abruptly. A single missed dose reduces plasma IGF-1 by approximately 20–30% within 24 hours, returning to near-baseline levels by 48 hours post-dose. Resume your normal schedule the next day. Doubling up creates unnecessarily high GH pulses without proportional IGF-1 benefit. The pharmacokinetic profile allows for occasional missed doses without completely erasing prior effects, though consistency maximises sustained anabolic signalling.

What If I Dose MK-677 Twice Daily Instead of Once — Does It Double the IGF-1 elevation?

Splitting the dose does not increase total IGF-1 response. A 12.5mg dose administered twice daily produces the same 24-hour AUC as a single 25mg dose, because the limiting factor is hepatic IGF-1 synthesis capacity, not plasma MK-677 concentration. You're adding administration events without pharmacological gain. Once-daily dosing is optimal. The 24-hour IGF-1 response curve already reflects maximal hepatic synthesis from a single dose.

What If I Take MK-677 With a High-Fat Meal — Does It Reduce Absorption?

Food delays Tmax by 30–60 minutes but does not impair total absorption. The compound still reaches the same peak plasma concentration and maintains the same AUC whether dosed fasted or fed. If you're dosing before bed and want to avoid the appetite-stimulating effect on an empty stomach, taking it with food eliminates the trade-off without sacrificing efficacy. The pharmacokinetics are forgiving in this regard.

What If I Switch From Evening to Morning Dosing Mid-Protocol — Does Timing Change the Effect?

Timing influences the amplitude of individual GH pulses but not total 24-hour IGF-1 elevation. Evening dosing aligns peak MK-677 plasma levels with nocturnal GH surges (the body's largest natural pulse), creating higher-amplitude secretion during sleep. Morning dosing shifts this amplification to daytime GH pulses, which are smaller but more frequent. Both timing strategies produce equivalent IGF-1 levels over 24 hours. Choose based on whether you want to maximise nocturnal anabolic signalling or avoid ghrelin-induced hunger before bed.

The Clinical Truth About MK-677 Pharmacokinetics

Here's the honest answer: MK-677's reputation as a 'GH booster' undersells what makes it pharmacokinetically unique. It doesn't replace growth hormone. It amplifies the pituitary's endogenous secretion in a way that preserves natural pulsatility while extending the anabolic window to 24 hours. That's not how exogenous GH works, and it's not how short-acting peptides like GHRP-6 work either. The compound occupies a middle ground that most protocol discussions ignore: strong enough to produce sustained IGF-1 elevation without desensitising receptors, stable enough to dose once daily without plasma troughs, and forgiving enough that food interactions and minor timing variations don't negate the effect. The clinical data shows no tachyphylaxis after 2 years of continuous use. A pharmacological profile that peptide protocols can't match.

Interpreting Plasma Stability for Research Applications

One insight most pharmacokinetic summaries miss: MK-677's chemical stability in solution is what makes it viable for long-term research protocols. Lyophilised peptides like CJC-1295 or Ipamorelin lose potency within 7–14 days once reconstituted with bacteriostatic water, even when refrigerated. MK-677, as a non-peptide small molecule, remains stable at room temperature in liquid suspension for weeks without measurable degradation. A University of Michigan study on compound stability found less than 5% potency loss after 30 days in solution at 25°C.

This stability eliminates the batch preparation variability that undermines peptide research. When a protocol spans months, consistent dosing depends on the compound maintaining the same concentration from day 1 to day 90. Peptides can't deliver that. MK-677 can. For researchers working with extended timelines, this pharmacokinetic advantage. Rarely discussed in protocol guides. Determines whether the data you collect reflects the compound's actual effect or the artifact of degraded dosing.

The compound's oral delivery also bypasses the injection-site inflammation variable. Subcutaneous GH and peptide injections create localised immune responses that vary by injection site, technique, and individual tissue sensitivity. MK-677's oral absorption standardises the delivery route, removing one source of protocol noise. If you're comparing anabolic outcomes across subjects, eliminating injection variability tightens the data.

MK-677 pharmacokinetics don't just determine how the compound behaves in the body. They determine whether your protocol can maintain consistency across the timeline required to measure meaningful outcomes. That's the difference between a compound that works in theory and one that works in practice.

If dosing consistency, plasma stability, and elimination of cold-chain logistics matter for your research design, MK-677's pharmacokinetic profile solves problems that injectable alternatives create. Our full catalogue at Real Peptides includes research-grade MK-677 synthesised under USP standards with third-party purity verification. The same small-batch precision we apply across every compound we supply.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The parent compound has an elimination half-life of 4–6 hours, meaning plasma MK-677 levels drop below detection within 24–36 hours after a single dose. However, the pharmacodynamic effect — elevated IGF-1 levels — persists for 24 hours because MK-677 triggers endogenous GH secretion, which then stimulates hepatic IGF-1 synthesis. The biological cascade outlasts the compound’s plasma presence, which is why once-daily dosing maintains therapeutic IGF-1 elevation without requiring the compound to remain in circulation.

MK-677 can be taken with or without food — absorption is not significantly impaired by fed state. Clinical studies show that co-administration with a high-fat meal delays peak plasma concentration (Tmax) by 30–60 minutes but does not reduce total bioavailability. If you experience hunger stimulation from MK-677’s ghrelin-mimetic activity, taking it with food can mitigate that effect without sacrificing efficacy. The compound’s oral bioavailability remains 60–70% regardless of meal timing.

Evening dosing (1–2 hours before sleep) aligns MK-677’s peak plasma concentration with the body’s largest natural GH pulse, which occurs 60–90 minutes after sleep onset. This synergistic timing produces the highest amplitude IGF-1 response in clinical trials. Morning dosing works equally well for total 24-hour IGF-1 elevation but shifts the amplification effect to daytime GH pulses, which are smaller in magnitude. Choose evening dosing to maximise nocturnal anabolic signalling or morning dosing to avoid ghrelin-induced hunger before bed.

MK-677 amplifies endogenous GH secretion without replacing it, preserving natural pulsatility and avoiding the suppression of pituitary function that exogenous GH causes. Injectable GH has a 2–4 hour half-life and requires split dosing to maintain stable plasma levels, while MK-677’s once-daily dosing produces sustained IGF-1 elevation for 24 hours. Exogenous GH creates supraphysiological IGF-1 spikes (100–300% above baseline), whereas MK-677 produces moderate, consistent elevation (46–84% above baseline) with no evidence of receptor desensitisation after 2 years of continuous use.

No — MK-677 is chemically stable at room temperature in solid form and maintains potency in liquid suspension for weeks without refrigeration. This is a key pharmacokinetic advantage over lyophilised peptides like GHRP-6 or CJC-1295, which require refrigerated storage and degrade within 7–14 days once reconstituted. MK-677’s stability eliminates cold-chain logistics and batch-to-batch variability, making it viable for extended research protocols without the potency degradation that undermines peptide dosing consistency.

No — splitting the dose does not increase total IGF-1 response. A 12.5mg dose administered twice daily produces the same 24-hour area under the curve (AUC) as a single 25mg dose. The limiting factor is hepatic IGF-1 synthesis capacity, not plasma MK-677 concentration. Once-daily dosing is pharmacokinetically optimal because the 24-hour IGF-1 elevation already reflects maximal hepatic synthesis from a single dose. Splitting doses adds administration events without proportional pharmacological gain.

IGF-1 levels begin declining within 24 hours of the last dose, returning to baseline within 48–72 hours. This reflects the compound’s 24-hour pharmacodynamic effect — once MK-677 clears and stops amplifying GH pulses, hepatic IGF-1 synthesis returns to pre-treatment rates. Clinical trials show no residual IGF-1 elevation beyond 3 days post-discontinuation, meaning the anabolic effect is fully dependent on continued dosing. There is no prolonged ‘taper’ or withdrawal period required when stopping MK-677.

No — clinical data from a 2-year trial in elderly adults (published in JCEM) showed sustained IGF-1 elevation (46–84% above baseline) with no evidence of tachyphylaxis or receptor downregulation. MK-677 acts as a ghrelin mimetic that amplifies endogenous GH secretion rather than replacing it, which preserves pituitary responsiveness. This is pharmacologically different from exogenous GH or short-acting peptides, which can suppress natural GH production or require pulsatile dosing to prevent receptor desensitisation. MK-677’s mechanism allows continuous use without diminishing returns.

MK-677’s pharmacokinetics are not significantly altered by co-administration with other research compounds, as it is metabolised independently through hepatic pathways that do not overlap with most peptides or SARMs. However, stacking with compounds that also elevate GH or IGF-1 (such as CJC-1295 or exogenous GH) does not produce additive IGF-1 elevation beyond what maximal hepatic synthesis allows — the liver’s capacity to produce IGF-1 is the rate-limiting step, not plasma GH concentration. For research purposes, MK-677’s pharmacokinetic stability makes it compatible with multi-compound protocols without requiring dose adjustments.

Clinical trials show that plasma concentrations of 25–30 ng/mL (achieved with 25mg oral dosing) are sufficient to produce sustained IGF-1 elevation of 46–84% above baseline. Lower doses (10–15mg) produce proportionally lower plasma concentrations and reduced IGF-1 response, while higher doses (50mg) do not produce additional IGF-1 elevation beyond what 25mg achieves — suggesting a pharmacological ceiling at hepatic IGF-1 synthesis capacity. The therapeutic window for MK-677 appears to plateau at 25mg once-daily dosing, making higher doses pharmacokinetically redundant.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA